We note that previous studies that have used antibodies to detect Tau acetylated at Lys174 have employed an in-house generated reagent [105, 117] and, importantly, that not all studies have detected this modification in AD patient brain samples, even when employing highly sensitive detection techniques [163], suggesting that it may either be present at very low levels or that its levels are highly variable across donor populations. Here, MAPT is linked to Alzheimer disease.